Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
- Conditions
- Gastric CancerEsophageal CancerGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 8
- Registration Number
- NCT00848783
- Locations
- 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸NYU Cancer Center, New York, New York, United States
🇺🇸Norris Cancer Center, Los Angeles, California, United States
Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
- Conditions
- Advanced Gastric CancerStomach Neoplasms
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00842244
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
- Conditions
- Advanced Gastric Cancer
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Peking University
- Target Recruit Count
- 45
- Registration Number
- NCT00842491
- Locations
- 🇨🇳
Department of GI Oncology, Peking University, School of Oncology, Beijing, Beijing, China
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 991
- Registration Number
- NCT00829166
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 84
- Registration Number
- NCT00828672
- Locations
- 🇧🇪
H. Hartziekenhuis, Roeselare, Belgium
🇧🇪Erasme Hospital, Brussels, Belgium
🇧🇪Clinique Sainte Elisabeth, Namur, Belgium
TaxXel: Taxotere and Xeloda in Esophageal Cancer
- Conditions
- Cancer of the EsophagusGastric Cardia Carcinoma
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 93
- Registration Number
- NCT00821912
- Locations
- 🇳🇴
Haukeland universitetssykehus, Bergen, Norway
🇸🇪Malmö General University Hospital, Malmö, Sweden
🇸🇪Västerås Central Hospital, Västerås, Sweden
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
- Conditions
- Metastases, Brain
- Interventions
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT00820222
- Locations
- 🇬🇧
Novartis Investigative Site, Worthing, United Kingdom
Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Biological: panitumumabDrug: capecitabineProcedure: therapeutic conventional surgeryRadiation: 3-dimensional conformal radiation therapy
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 68
- Registration Number
- NCT00814619
- Locations
- 🇨🇭
Hirslanden Klinik Aarau, Aarau, Switzerland
🇨🇭City Hospital Triemli, Zurich, Switzerland
🇨🇭UniversitaetsSpital Zuerich, Zurich, Switzerland
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- University Hospital, Limoges
- Target Recruit Count
- 20
- Registration Number
- NCT00812864
- Locations
- 🇫🇷
CHU Limoges, Limoges Cedex, Province, France
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 111
- Registration Number
- NCT00798252
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.